Compare OR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OR | PCVX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Canada | United States |
| Employees | 23 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.7B |
| IPO Year | 2014 | 2020 |
| Metric | OR | PCVX |
|---|---|---|
| Price | $40.10 | $62.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $47.00 | ★ $88.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $100.08 | N/A |
| Revenue Next Year | $13.87 | N/A |
| P/E Ratio | $55.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.08 | $28.09 |
| 52 Week High | $48.06 | $65.00 |
| Indicator | OR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 65.54 |
| Support Level | $38.38 | $42.30 |
| Resistance Level | $42.25 | $65.00 |
| Average True Range (ATR) | 1.62 | 2.28 |
| MACD | 0.50 | 0.62 |
| Stochastic Oscillator | 72.41 | 95.44 |
OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.